Abolishing coinsurance for oral antihyperglycemic agents: Effects on social insurance budgets

American Journal of Managed Care

Volumn 17, Issue 2, 2011, Pages 130-135

  Athanasakis, Kostas ^a   Skroumpelos, Anastasis G ^a   Tsiantou, Vassiliki ^a   Milona, Katerina ^a   Kyriopoulos, John ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT;

ARTICLE; COST CONTROL; DIABETES MELLITUS; DRUG COST; ECONOMIC ASPECT; GREECE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MATHEMATICAL MODEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOCIAL INSURANCE; VALIDITY;

ADMINISTRATION, ORAL; BUDGETS; COST SAVINGS; DEDUCTIBLES AND COINSURANCE; DIABETES MELLITUS, TYPE 2; GREECE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; MODELS, THEORETICAL; SENSITIVITY AND SPECIFICITY; SOCIAL SECURITY;

EID: 79960253326     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. World Health Organization. Preventing Chronic Diseases: A Vital Investment. Geneva, Switzerland: World Health Organization; 2005.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-1431.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
4. Panagiotakos DB, Pitsavos C, Chrysochoou C, Stefanadis C. The epidemiology of type II diabetes mellitus in Greek adults: the Atica study. Diabet Med. 2005;22(11):1581-1588. (Pubitemid 41641167)
5. Athanasakis K, Ollandezos M, Angeli A, Gregoriou A, Geitona M, Kyriopoulos J. Estimating the direct cost of type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. Diabet Med. 2010;27(6):679-684.
6. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):1-20.
7. Jönsson B; CODE-2 Advisory Board. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45(7):S5-S12. (Pubitemid 34762208)
8. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and the progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
9. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care. 2007;30(suppl 1):S4-S41.
10. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20(12):1847-1853. (Pubitemid 27522894)
11. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285(2):182-189. (Pubitemid 32048520)
12. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 2002;25(3):476-481. (Pubitemid 41103339)
13. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care. 2001;24(1):51-55. (Pubitemid 32104219)
14. Shetty SS, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005;11(7):559-564.
15. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
16. Brown JB, Nichol GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther. 1999;21(6):1045-1057. (Pubitemid 29326162)
17. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24(8):1411-1415. (Pubitemid 33716429)
18. Pugh MJ, Anderson J, Pogach LM, Berlowitz DR. Differential adoption of pharmacotherapy recommendations for type 2 diabetes by generalists and specialists. Med Care Res Rev. 2003;60(2):178-200. (Pubitemid 36605432)
19. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224. (Pubitemid 38579798)
20. Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008;34(4):692-697.
21. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-740. (Pubitemid 41608213)
22. Karter AJ, Stevens MR, Herman WH, et al; Translating Research Into Action for Diabetes Study Group. Out-of-pocket costs and diabetes preventive services: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care. 2003;26(8):2294-2299.
23. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27(2):384-391. (Pubitemid 38174062)
24. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5)(suppl):S170-S176.
25. Colombi AM, Yu-Isenberg K, Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med. 2008;50(5):535-541. (Pubitemid 351677636)
26. Joyce GF, Goldman DP, Karaca-Mandic P, Zheng Y. Pharmacy benefit caps and the chronically ill. Health Aff (Millwood). 2007;26(5):1333-1344.
27. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9):509-517. (Pubitemid 44412033)
28. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12(spec no.):SP11-SP19.
29. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25(6):1015-1021. (Pubitemid 41110487)
30. Contoyannis P, Hurley J, Grootendorst P, Jeon SH, Tamblyn R. Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Econ. 2005;14(9):909-923.
31. Sherman BW, Frazee SG, Fabius RJ, Broome RA, Manfred JR, Davis JC. Impact of workplace health services on adherence to chronic medications. Am J Manag Care. 2009;15(7):e53-e59.
32. Liatis S, Thomakos P, Papaoikonomou S, et al. Trends in the management of type 2 diabetes and its prescription drug cost in Greece (1998 & 2006). Exp Clin Endocrinol Diabetes. 2009;117(9):505-510.
33. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350. (Pubitemid 38656301)
34. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143(2):89-99.
35. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95(1):68-71. (Pubitemid 34131538)
36. Alexander DL, Flynn JE, Linkins LA. Estimates of the demand for ethical pharmaceutical drugs across countries and time. Applied Econ. 1994;26(8):821-826.